The critical role of clinical pharmacology in geriatric psychopharmacology

B. G. Pollock, C. E. Forsyth, Robert Bies

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

There is limited geriatrics-oriented clinical pharmacological information available to guide pharmacotherapy in latelife psychiatric disorders. In this paper, we review available data on interindividual differences in drug exposure and central nervous system functioning, amplified by drug-drug interactions in the elderly, that may contribute to variable responses to treatment and significant adverse drug effects. The inclusion of greater numbers of elderly persons in clinical trials and the vigorous application of clinical pharmacologic methodology (i.e., pharmacoepidemiology, population pharmacokinetic modeling, and pharmacogenetics) will be critical for improving safety and personalization of drug and dose selection for elderly patients.

Original languageEnglish (US)
Pages (from-to)89-93
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume85
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Psychopharmacology
Clinical Pharmacology
Geriatrics
Pharmacoepidemiology
Pharmaceutical Preparations
Central Nervous System Agents
Pharmacogenetics
Drug Interactions
Patient Selection
Psychiatry
Pharmacokinetics
Clinical Trials
Pharmacology
Safety
Drug Therapy
Population
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The critical role of clinical pharmacology in geriatric psychopharmacology. / Pollock, B. G.; Forsyth, C. E.; Bies, Robert.

In: Clinical Pharmacology and Therapeutics, Vol. 85, No. 1, 01.2009, p. 89-93.

Research output: Contribution to journalArticle

@article{edf0352c32ea463296ccba901a7a9b41,
title = "The critical role of clinical pharmacology in geriatric psychopharmacology",
abstract = "There is limited geriatrics-oriented clinical pharmacological information available to guide pharmacotherapy in latelife psychiatric disorders. In this paper, we review available data on interindividual differences in drug exposure and central nervous system functioning, amplified by drug-drug interactions in the elderly, that may contribute to variable responses to treatment and significant adverse drug effects. The inclusion of greater numbers of elderly persons in clinical trials and the vigorous application of clinical pharmacologic methodology (i.e., pharmacoepidemiology, population pharmacokinetic modeling, and pharmacogenetics) will be critical for improving safety and personalization of drug and dose selection for elderly patients.",
author = "Pollock, {B. G.} and Forsyth, {C. E.} and Robert Bies",
year = "2009",
month = "1",
doi = "10.1038/clpt.2008.229",
language = "English (US)",
volume = "85",
pages = "89--93",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The critical role of clinical pharmacology in geriatric psychopharmacology

AU - Pollock, B. G.

AU - Forsyth, C. E.

AU - Bies, Robert

PY - 2009/1

Y1 - 2009/1

N2 - There is limited geriatrics-oriented clinical pharmacological information available to guide pharmacotherapy in latelife psychiatric disorders. In this paper, we review available data on interindividual differences in drug exposure and central nervous system functioning, amplified by drug-drug interactions in the elderly, that may contribute to variable responses to treatment and significant adverse drug effects. The inclusion of greater numbers of elderly persons in clinical trials and the vigorous application of clinical pharmacologic methodology (i.e., pharmacoepidemiology, population pharmacokinetic modeling, and pharmacogenetics) will be critical for improving safety and personalization of drug and dose selection for elderly patients.

AB - There is limited geriatrics-oriented clinical pharmacological information available to guide pharmacotherapy in latelife psychiatric disorders. In this paper, we review available data on interindividual differences in drug exposure and central nervous system functioning, amplified by drug-drug interactions in the elderly, that may contribute to variable responses to treatment and significant adverse drug effects. The inclusion of greater numbers of elderly persons in clinical trials and the vigorous application of clinical pharmacologic methodology (i.e., pharmacoepidemiology, population pharmacokinetic modeling, and pharmacogenetics) will be critical for improving safety and personalization of drug and dose selection for elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=57749191241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749191241&partnerID=8YFLogxK

U2 - 10.1038/clpt.2008.229

DO - 10.1038/clpt.2008.229

M3 - Article

VL - 85

SP - 89

EP - 93

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -